Photodynamic Therapy in Unresectable Cholangiocarcinoma: Not for the Uncommitted
Clinical Endoscopy
;
: 390-394, 2013.
Article
in English
| WPRIM
| ID: wpr-200376
ABSTRACT
BACKGROUND/AIMS:
Photodynamic therapy (PDT) in unresectable cholangiocarcinoma has been associated with improved survival. We report a single tertiary care center experience over the past 6 years.METHODS:
Fifty-five patients with unresectable cholangiocarcinoma received PDT between 2004 and 2010. Plastic stents were placed after PDT to prevent cholangitis.RESULTS:
Twenty-seven patients (49%) showed Bismuth type IV, 22 (41%) showed Bismuth type III, and six (10%) showed Bismuth type I and II. Twenty patients (37%) received chemotherapy and radiation therapy, five (9%) received chemotherapy only; and one (2%) received radiation therapy only. Mean number of PDT sessions was 1.9+/-1.5 sessions (range, 1 to 9). Mean survival duration was 293+/-266 days (median, 190; range, 25 to 1,332). PDT related complications included three (5%) facial burn, three (5%) photosensitivity, and two (3%) rash. Kaplan-Meier analysis comparing the survival means of patients who received PDT and chemotherapy/radiation therapy (median survival 257 days; 95% confidence interval [CI], 166 to 528) versus who received PDT only (median survival 183 days; 95% CI, 129 to 224) showed no significant difference (log-rank p=0.20).CONCLUSIONS:
PDT has a measurable impact on survival in unresectable cholangiocarcinoma but requires aggressive stenting posttherapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Photochemotherapy
/
Plastics
/
Triazenes
/
Bismuth
/
Burns
/
Stents
/
Cholangiocarcinoma
/
Exanthema
/
Kaplan-Meier Estimate
/
Tertiary Care Centers
Limits:
Humans
Language:
English
Journal:
Clinical Endoscopy
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS